Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of JNJ-88549968 in CALR-mutated essential thrombocythemia or myelofibrosis
jRCT2031260129Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2026
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of JNJ-88549968 and ruxolitinib in thrombocythemia, myelofibrosis (MF) and myeloproliferative disorder (MPD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with dose-limiting toxicity, Number of participants with adverse events and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
JNJ-88549968ruxolitinib
03
Conditions
thrombocythemiamyelofibrosis (MF)myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on jRCT2031260129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260129.